<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911107-0049</DOCNO><DOCID>911107-0049.</DOCID><HL>   Technology Brief -- T Cell Sciences Inc.:   Joint Development Accord   With AB Astra Disclosed</HL><DATE>11/07/91</DATE><SO>WALL STREET JOURNAL (J), NO PAGE CITATION</SO><CO>   S.AST TCEL</CO><MS>CONSUMER NON-CYCLICAL (NCY)TECHNOLOGY (TEC)</MS><IN>MEDICAL SUPPLIES, EYEGLASS MANUFACTURERS (MDS)MEDICAL andamp; BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)</IN><RE>EUROPE (EU)MASSACHUSETTS (MA)NORTH AMERICA (NME)SCANDINAVIA (SCA)SWEDEN (SW)UNITED STATES (US)</RE><LP>   T Cell Sciences Inc., Cambridge, Mass., disclosed a jointdevelopment and marketing agreement with the Swedishpharmaceutical company AB Astra covering T Cell's antigenreceptor technology.   It will substantially boost T Cell's revenue, which was$2.1 million in the latest reported quarter, ended July 31.</LP><TEXT>   Revenue from Astra to T Cell will amount to about $15million over 24 months, with further research investmentoptions by Astra that could increase that amount by anadditional $17 million or more, T Cell said.   A T Cell spokesman said the agreement is a validation ofthe company's research in genetically engineered substancesthat may be effective in treating autoimmune diseases such asrheumatoid arthritis, multiple sclerosis, T cell cancers andother disorders.</TEXT></DOC>